Work

In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma

Year: 2022

Type: article

Abstract: Hepatocellular carcinoma (HCC) is the most prevalent cancer of the liver and is a leading cause of cancer deaths worldwide. The multikinase inhibitor sorafenib has long been used to treat HCC because it was shown to extend survival by 3 months.1 Although other drugs have recently been approved for therapy of HCC based on slightly improved outcomes,2 there is still a pressing need for new and effective treatments. Sequencing technologies have identified hundreds of prognostic genes in HCC.3 Nevertheless, correlation does not equate to functionality.

Source: Gastro Hep Advances

DOI: 10.1016/j.gastha.2022.05.014